当前位置： SCI文献检索 > Drug Metabolism and Pharmacokinetics期刊下所有文献 > Possible involvement of singlet oxygen species as multiple oxidants in p450 catalytic reactions.

Possible involvement of singlet oxygen species as multiple oxidants in p450 catalytic reactions.

Abstract：

:Cytochrome P450 (P450) constitutes a superfamily of enzymes which activate dioxygen and carry out monooxygenation reactions of large numbers of endogenous and xenobiotic compounds. Drug metabolism is a particularly important P450 function, and, therefore, elucidating the metabolic products and pathways of drugs is essential for drug development. To explain the substrate selectivity of P450 reactions, it is necessary to understand the formation of multiple activated oxygen species to determine the type of catalyzed reactions, in addition to conducting structure analyses of P450s. Although an oxo-Fe(IV)-porphyrin-pi-cation radical is regarded as an activated oxygen species in P450 reactions, a nucleophilic Fe(III)-peroxo species has also been proposed as another oxidant. In the past decade, various studies indicated that P450-catalyzed oxygenations are complex, and that a single reaction pathway cannot explain all of the experimental results. In addition, the microsomal P450 system is known to generate reactive oxygen species (ROS). However, the contribution of ROS to P450 reactions remains unclear. We recently found that singlet oxygen (1O2) was involved in both several rat liver microsomal P450 reactions and four human CYP subfamily activities, as confirmed by the ESR spin-trapping method. In this review, we describe the studies that have been conducted on the detection and characterization of ROS in P450 reactions related to drug metabolism that involve the possibility of 1O2 in the P450 catalytic cycle. Gaining an understanding of the activated oxygen species that determine the type of drug metabolism will help us to predict the important metabolites formed.

journal_name

Drug Metab Pharmacokinet

journal_title

Drug metabolism and pharmacokinetics

authors

Yasui H,Hayashi S,Sakurai H

doi

10.2133/dmpk.20.1

subject

Has Abstract

pub_date

2005-02-01 00:00:00

pages

1-13

issue

1

eissn

1347-4367

issn

1880-0920

pii

JST.JSTAGE/dmpk/20.1

journal_volume

20

pub_type

杂志文章,评审

相关文献

Drug Metabolism and Pharmacokinetics文献大全
  • Paroxetine decreased plasma exposure of glyburide partly via inhibiting intestinal absorption in rats.

    abstract：:Accumulating evidences have shown that diabetes is often accompanied with depression, thus it is possible that oral antidiabetic agent glyburide and antidepressive agent paroxetine are co-administered in diabetic patients. The aim of this study was to assess interactions between glyburide and paroxetine in rats. Effec...

    journal_title：Drug metabolism and pharmacokinetics

    pub_type： 杂志文章

    doi：10.1016/j.dmpk.2015.02.004

    authors： Jiang S,Zhao W,Chen Y,Zhong Z,Zhang M,Li F,Xu P,Zhao K,Li Y,Liu L,Liu X

    更新日期：2015-06-01 00:00:00

  • Effect of hydrocotarnine on cytochrome P450 and P-glycoprotein.

    abstract：:The injectable form of oxycodone contains hydrocotarnine that is supposed to potentiate the analgesic effect of oxycodone with unknown mechanism(s). In this study, the effects of hydrocotarnine on the cytochrome P450 (CYP) and P-glycoprotein (P-gp) were investigated. Hydrocotarnine did not induce a significant change ...

    journal_title：Drug metabolism and pharmacokinetics

    pub_type： 杂志文章

    doi：10.2133/dmpk.24.108

    authors： Ito K,Kubota Y,Toda T,Suto S,Ikarashi N,Sugiyama K

    更新日期：2009-01-01 00:00:00

  • Physiologically-based modeling of monoclonal antibody pharmacokinetics in drug discovery and development.

    abstract：:Over the past few decades, monoclonal antibodies (mAbs) have become one of the most important and fastest growing classes of therapeutic molecules, with applications in a wide variety of disease areas. As such, understanding of the determinants of mAb pharmacokinetic (PK) processes (absorption, distribution, metabolis...

    journal_title：Drug metabolism and pharmacokinetics

    pub_type： 杂志文章,评审

    doi：10.1016/j.dmpk.2018.11.002

    authors： Glassman PM,Balthasar JP

    更新日期：2019-02-01 00:00:00

  • Decrease in ciprofloxacin absorption by polyvalent metal cations is not fully attributable to chelation or adsorption.

    abstract：:The drug interaction between new quinolone antibiotics (NQs) and polyvalent metal cation products, leading to a significant decrease in the absorption of NQ, is considered to be attributable to the formation of poorly absorbable chelate and physicochemical adsorption of NQs to cation products. To clarify the mechanism...

    journal_title：Drug metabolism and pharmacokinetics

    pub_type： 杂志文章

    doi：10.2133/dmpk.dmpk-14-rg-001

    authors： Imaoka A,Hattori M,Akiyoshi T,Ohtani H

    更新日期：2014-01-01 00:00:00

  • Drug-induced idiosyncratic hepatotoxicity: prevention strategy developed after the troglitazone case.

    abstract：:Troglitazone induced an idiosyncratic, hepatocellular injury-type hepatotoxicity in humans. Statistically, double null genotype of glutathione S-transferase isoforms, GSTT1 and GSTM1, was a risk factor, indicating a low activity of the susceptible patients in scavenging chemically reactive metabolites. CYP3A4 and CYP2...

    journal_title：Drug metabolism and pharmacokinetics

    pub_type： 杂志文章,评审

    doi：10.2133/dmpk.dmpk-10-rv-090

    authors： Ikeda T

    更新日期：2011-01-01 00:00:00

  • New SRM data dependent exclusion (MS)n measurement for structural determination of drug metabolites using LC/ESI/Ion trap MS.

    abstract：:New SRM (selected reaction monitoring) data dependent exclusion (MS)(n) measurement makes it possible to obtain MS(3) fragmentation data for all MS(2) fragments, useful for structural determination of drug metabolites using ESI ion trap. MS(2) fragments are produced by cleavage of all protonated molecules at the lone ...

    journal_title：Drug metabolism and pharmacokinetics

    pub_type： 杂志文章

    doi：10.2133/dmpk.18.390

    authors： Tozuka Z,Kaneko H,Shiraga T,Beppu M,Niwa T,Kawamura A,Kagayama A

    更新日期：2003-01-01 00:00:00

  • Effect of protein binding of pilsicainide on the pharmacokinetics.

    abstract：:To evaluate the effect of protein binding of pilsicainide on its clearance and the contribution of protein binding to optimized pilsicainide therapy, clinical laboratory and pharmacokinetic data were studied in 160 Japanese inpatients (Study 1) and 18 Japanese inpatients (Study 2). To determine the relation between pr...

    journal_title：Drug metabolism and pharmacokinetics

    pub_type： 杂志文章

    doi：10.2133/dmpk.20.183

    authors： Fukumoto K,Tanemura M,Tsuchishita Y,Kusumoto M,Matsumoto K,Kamakura S,Ueno K

    更新日期：2005-06-01 00:00:00

  • Rapid stimulating effect of the antiarrhythmic agent amiodarone on absorption of organic anion compounds.

    abstract：:In a clinical setting, changes in pharmacokinetics due to drug-drug interactions can often directly affect the therapeutic safety and efficacy of drugs. Recently, interest has been shown in drug-drug interactions in the intestine. It is now recognized that changes in the functions of drug transporters substantially in...

    journal_title：Drug metabolism and pharmacokinetics

    pub_type： 杂志文章

    doi：10.2133/dmpk.dmpk-12-rg-010

    authors： Segawa M,Ogura J,Seki S,Itagaki S,Takahashi N,Kobayashi M,Hirano T,Yamaguchi H,Iseki K

    更新日期：2013-01-01 00:00:00

  • Organic cation transporter Octn1-mediated uptake of food-derived antioxidant ergothioneine into infiltrating macrophages during intestinal inflammation in mice.

    abstract：:OCTN1/SLC22A4 is expressed on apical membranes of small intestine, and is involved in gastrointestinal absorption of its substrates, including the food-derived antioxidant ergothioneine (ERGO). ERGO concentration in circulating blood of patients with inflammatory bowel disease (Crohn's disease) is lower than that in h...

    journal_title：Drug metabolism and pharmacokinetics

    pub_type： 杂志文章

    doi：10.1016/j.dmpk.2015.02.003

    authors： Shimizu T,Masuo Y,Takahashi S,Nakamichi N,Kato Y

    更新日期：2015-06-01 00:00:00

  • Assessment of induction of cytochrome P450 by NO-1886 (ibrolipim), a lipoprotein lipase-promoting agent, in primary cultures of human hepatocytes and in female rat liver.

    abstract：:The mRNA levels of human cytochrome P450 (CYP)2Cs and CYP3As in primary cultures of freshly isolated human hepatocytes were assessed after exposure to NO-1886 and rifampicin, a typical inducer of CYP3As. mRNA levels were analyzed by real-time RT-PCR using an ABI PRISM 7700 Sequence Detector system. Exposure to NO-1886...

    journal_title：Drug metabolism and pharmacokinetics

    pub_type： 杂志文章

    doi：10.2133/dmpk.21.19

    authors： Morioka Y,Nishimura M,Imai T,Suzuki S,Harada M,Satoh T,Naito S

    更新日期：2006-02-01 00:00:00

  • Genetic variations of the ABC transporter gene ABCB11 encoding the human bile salt export pump (BSEP) in a Japanese population.

    abstract：:The bile salt export pump (BSEP) encoded by ABCB11 is located in the canalicular membrane of hepatocytes and mediates the secretion of numerous conjugated bile salts into the bile canaliculus. In this study, 28 ABCB11 exons (including non-coding exon 1) and their flanking introns were comprehensively screened for gene...

    journal_title：Drug metabolism and pharmacokinetics

    pub_type： 杂志文章

    doi：10.2133/dmpk.24.277

    authors： Kim SR,Saito Y,Itoda M,Maekawa K,Kawamoto M,Kamatani N,Ozawa S,Sawada J

    更新日期：2009-01-01 00:00:00

  • Significance of aldehyde oxidase during drug development: Effects on drug metabolism, pharmacokinetics, toxicity, and efficacy.

    abstract：:Aldehyde oxidase contributes to drug metabolism and pharmacokinetics (PK), and a few clinical studies were discontinued because of aldehyde oxidase metabolism. Its AOX1, AOX3, AOX3L1, and AOX4 isoforms are expressed in mammals, and species differences in expression profiles reflect differences in drug metabolism and P...

    journal_title：Drug metabolism and pharmacokinetics

    pub_type： 杂志文章,评审

    doi：10.1016/j.dmpk.2014.10.009

    authors： Sanoh S,Tayama Y,Sugihara K,Kitamura S,Ohta S

    更新日期：2015-02-01 00:00:00

  • Optimal dosage regimen of meropenem for pediatric patients based on pharmacokinetic/pharmacodynamic considerations.

    abstract：:A population pharmacokinetic (PK) model for meropenem in Japanese pediatric patients with various infectious diseases was developed based on 116 plasma concentrations from 50 pediatric patients. The population PK parameters developed in this analysis are useful for calculation of the percent time above minimum inhibit...

    journal_title：Drug metabolism and pharmacokinetics

    pub_type： 杂志文章

    doi：10.2133/dmpk.dmpk-11-rg-027

    authors： Ohata Y,Tomita Y,Nakayama M,Kozuki T,Sunakawa K,Tanigawara Y

    更新日期：2011-01-01 00:00:00

  • Effect of CAR polymorphism on the pharmacokinetics of artemisinin in healthy Chinese subjects.

    abstract：:Repeated pretreatment with the antimalarial drug artemisinin (QHS) could lead to reduced exposure to the parent drug, which is mainly mediated by auto-induction of CYP2B6 activity. CYP2B6 is most sensitive to the inductive effect of constitutive androstane receptor (CAR), which can be activated by QHS. CYP2B6 polymorp...

    journal_title：Drug metabolism and pharmacokinetics

    pub_type： 临床试验,杂志文章

    doi：10.1016/j.dmpk.2014.10.008

    authors： Zang M,Zhao L,Zhu F,Li X,Yang A,Xing J

    更新日期：2015-02-01 00:00:00

  • A randomized, placebo-controlled, single ascending-dose study to assess the safety, tolerability, pharmacokinetics, and immunogenicity of subcutaneous tralokinumab in Japanese healthy volunteers.

    abstract：:Tralokinumab is a human monoclonal antibody in clinical development for asthma and atopic dermatitis that specifically neutralizes interleukin-13. This phase I, single-blind, randomized, placebo-controlled, single ascending-dose study assessed the safety, tolerability, pharmacokinetics (PK), and immunogenicity of subc...

    journal_title：Drug metabolism and pharmacokinetics

    pub_type： 杂志文章,随机对照试验

    doi：10.1016/j.dmpk.2017.12.001

    authors： Baverel P,She D,Piper E,Ueda S,Yoshioka T,Faggioni R,Gevorkyan H

    更新日期：2018-06-01 00:00:00

  • Bonitos with low content of malodorous trimethylamine as palliative care for self-reported Japanese trimethylaminuria subjects.

    abstract：:Trimethylaminuria is caused by excessive malodorous trimethylamine excreted via urine and body secretion by decreased hepatic flavin-containing monooxygenase 3 (FMO3) metabolic capacity for transforming non-odorous trimethylamine N-oxide. This study investigates foodstuff first in healthy volunteers for palliative car...

    journal_title：Drug metabolism and pharmacokinetics

    pub_type： 杂志文章

    doi：10.2133/dmpk.24.549

    authors： Shimizu M,Kozono M,Murayama N,Yamazaki H

    更新日期：2009-01-01 00:00:00

  • Association of hemoglobin levels, CYP3A5, and NR1I3 gene polymorphisms with tacrolimus pharmacokinetics in liver transplant patients.

    abstract：:Tacrolimus is a widely used immunosuppressant after organ transplantation. The narrow therapeutic window and individual variability in tacrolimus pharmacokinetics make management of this agent a great challenge. This study was undertaken to determine the association of clinical markers, cytochrome P450, family 3, subf...

    journal_title：Drug metabolism and pharmacokinetics

    pub_type： 杂志文章

    doi：10.2133/dmpk.dmpk-13-rg-095

    authors： Chen D,Guo F,Shi J,Zhang C,Wang Z,Fan J,Peng Z

    更新日期：2014-01-01 00:00:00

  • Molecular characterization of UDP-glucuronosyltransferases 3A and 8A in cynomolgus macaques.

    abstract：:UDP-glucuronosyltransferases (UGTs) are drug-metabolizing enzymes essential for the metabolism of endogenous substrates and xenobiotics. The cynomolgus macaque is a nonhuman primate species widely used in drug metabolism studies. The molecular characteristics of UGTs have been extensively investigated in humans, but t...

    journal_title：Drug metabolism and pharmacokinetics

    pub_type： 杂志文章

    doi：10.1016/j.dmpk.2020.05.001

    authors： Uno Y,Yamazaki H

    更新日期：2020-08-01 00:00:00

  • Novel multiple assessment of hepatocellular drug disposition in a single packaged procedure.

    abstract：UNLABELLED:Better prediction of drug disposition prior to the clinical trial is critical for the efficient development of new drugs. The purpose of this study is to develop a novel multiple assessment methodology of hepatocellular drug disposition from drug uptake to efflux including biliary and basolateral excretion, ...

    journal_title：Drug metabolism and pharmacokinetics

    pub_type： 杂志文章

    doi：10.1016/j.dmpk.2015.12.001

    authors： Takahashi R,Ichikawa H,Kanda K

    更新日期：2016-04-01 00:00:00

  • Five novel single nucleotide polymorphisms in the EPHX1 gene encoding microsomal epoxide hydrolase.

    abstract：:Five novel single nucleotide polymorphisms (SNPs) were found in the EPHX1 gene from 96 Japanese epileptic patients. The detected SNPs were as follows: 1) SNP, MPJ6_EX1009; GENE NAME, EPHX1 ACCESSION NUMBER, NT_004525.12; LENGTH, 25 bases; 5'-CCTCACTTCAGTG/ACTGGGCTTTGCC-3'. 2) SNP, MPJ6_EX1013; GENE NAME, EPHX1; ACCESS...

    journal_title：Drug metabolism and pharmacokinetics

    pub_type： 杂志文章

    doi：10.2133/dmpk.18.150

    authors： Shiseki K,Itoda M,Saito Y,Nakajima Y,Maekawa K,Kimura H,Goto Y,Saitoh O,Katoh M,Ohnuma T,Kawai M,Sugai K,Ohtsuki T,Suzuki C,Minami N,Ozawa S,Sawada J

    更新日期：2003-01-01 00:00:00

  • Association of ABCC2 genotype with efficacy of first-line FOLFIRI in Japanese patients with advanced colorectal cancer.

    abstract：:This exploratory retrospective study examined the effects of polymorphisms in transporter genes related to irinotecan pharmacokinetics and those in genes related to irinotecan pharmacodynamics on the efficacy of first-line combination chemotherapy with irinotecan, 5-fluorouracil, and folinic acid (leucovorin) (FOLFIRI...

    journal_title：Drug metabolism and pharmacokinetics

    pub_type： 杂志文章

    doi：10.2133/dmpk.dmpk-11-rg-128

    authors： Akiyama Y,Fujita K,Ishida H,Sunakawa Y,Yamashita K,Kawara K,Miwa K,Saji S,Sasaki Y

    更新日期：2012-01-01 00:00:00

  • Population pharmacokinetic analysis of a novel muscarinic receptor antagonist, imidafenacin, in healthy volunteers and overactive bladder patients.

    abstract：:The objectives of this study were to develop a population pharmacokinetic model of imidafenacin and to explore the factors that affect the pharmacokinetics of imidafenecin. A total of 2406 plasma samples were collected from 90 healthy volunteers and 457 patients with overactive bladder. We determined the plasma concen...

    journal_title：Drug metabolism and pharmacokinetics

    pub_type： 杂志文章

    doi：10.2133/dmpk.23.456

    authors： Ohno T,Nakade S,Nakayama K,Kitagawa J,Miyabe H,Konomi T,Miyata Y

    更新日期：2008-01-01 00:00:00

  • Role and relevance of PEPT2 in drug disposition, dynamics, and toxicity.

    abstract：:Pept2 knockout mice are an important tool to evaluate the evolving role and relevance of this proton-coupled oligopeptide transporter beyond drug disposition, where the transporter also modulates the pharmacodynamic and toxicodynamic effects of drug substrates. Our in vivo studies with glycylsarcosine in Pept2 knockou...

    journal_title：Drug metabolism and pharmacokinetics

    pub_type： 杂志文章,评审

    doi：10.2133/dmpk.23.236

    authors： Kamal MA,Keep RF,Smith DE

    更新日期：2008-01-01 00:00:00

  • Pharmacokinetics and bioavailability of tuftsin-derived T peptide, a promising antitumor agent, in beagles.

    abstract：:Tuftsin, a natural phagocytosis-stimulating tetrapeptide, had aroused much interest in tumor immunotherapy, but the poor pharmacokinetics hampered its clinical developments, for that it was extremely susceptible to degradation by enzymolysis in vivo. T Peptide (TP) was a newly designed tuftsin derivative aimed to enha...

    journal_title：Drug metabolism and pharmacokinetics

    pub_type： 杂志文章

    doi：10.1016/j.dmpk.2015.08.005

    authors： Gu R,He Y,Han S,Yuan S,An Y,Meng Z,Zhu X,Gan H,Wu Z,Li J,Zheng Y,Zhang L,Gao L,Dou G

    更新日期：2016-02-01 00:00:00

  • Applications of MALDI mass spectrometry imaging for pharmacokinetic studies during drug development.

    abstract：:The concentration and distribution of a drug or its metabolites in tissues are key factors for understanding drug efficacy or toxicity. Conventional pharmacokinetic studies show that the plasma concentration of a drug is often unrelated to the intra-tissue concentration. Moreover, it is difficult to predict the distri...

    journal_title：Drug metabolism and pharmacokinetics

    pub_type： 杂志文章,评审

    doi：10.1016/j.dmpk.2019.04.006

    authors： Nishidate M,Hayashi M,Aikawa H,Tanaka K,Nakada N,Miura SI,Ryu S,Higashi T,Ikarashi Y,Fujiwara Y,Hamada A

    更新日期：2019-08-01 00:00:00

  • Relationship between ABCB1 gene polymorphisms and severe neutropenia in patients with breast cancer treated with doxorubicin/cyclophosphamide chemotherapy.

    abstract：:Chemotherapy-induced neutropenia is one of the major adverse events which results in the reduction of chemotherapy. Doxorubicin is a substrate of the adenosine triphosphate-binding cassette subfamily B member 1 (ABCB1) transporter; reportedly, ABCB1 polymorphisms influence doxorubicin pharmacokinetics. We evaluated th...

    journal_title：Drug metabolism and pharmacokinetics

    pub_type： 杂志文章

    doi：10.1016/j.dmpk.2014.09.009

    authors： Ikeda M,Tsuji D,Yamamoto K,Kim YI,Daimon T,Iwabe Y,Hatori M,Makuta R,Hayashi H,Inoue K,Nakamichi H,Shiokawa M,Itoh K

    更新日期：2015-04-01 00:00:00

  • A novel variant allele of OATP-C (SLCO1B1) found in a Japanese patient with pravastatin-induced myopathy.

    abstract：:We have recently found that the frequency of OATP-C*15 is significantly higher in patients who experienced myopathy after receiving pravastatin or atorvastatin than in patients without myopathy. However, there were two patients who experienced pravastatin-induced myopathy despite the fact that they did not possess OAT...

    journal_title：Drug metabolism and pharmacokinetics

    pub_type： 杂志文章

    doi：10.2133/dmpk.19.453

    authors： Morimoto K,Oishi T,Ueda S,Ueda M,Hosokawa M,Chiba K

    更新日期：2004-12-01 00:00:00

  • Mechanism-based inactivation of cytochrome P450 2A6 and 2A13 by Rhinacanthus nasutus constituents.

    abstract：:  Human cytochrome P450 CYP2A6 and CYP2A13 catalyze nicotine metabolisms and mediate activation of tobacco-specific carcinogens including 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK) and 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanol (NNAL). In this study, we found rhinacanthins A, B, and C isolated from Rhinac...

    journal_title：Drug metabolism and pharmacokinetics

    pub_type： 杂志文章

    doi：10.2133/dmpk.dmpk-13-rg-048

    authors： Pouyfung P,Prasopthum A,Sarapusit S,Srisook E,Rongnoparut P

    更新日期：2014-01-01 00:00:00

  • Mutation in an adaptor protein PDZK1 affects transport activity of organic cation transporter OCTNs and oligopeptide transporter PEPT2.

    abstract：:Genetic polymorphisms in xenobiotic transporters have recently been clarified to be associated with change in drug distribution and disposition. To expand on recent identification of direct interaction and functional regulation of several transporters by a PDZ (PSD95, Dlg and ZO1) domain containing protein PDZK1, the ...

    journal_title：Drug metabolism and pharmacokinetics

    pub_type： 杂志文章

    doi：10.2133/dmpk.21.375

    authors： Sugiura T,Kato Y,Kubo Y,Tsuji A

    更新日期：2006-10-01 00:00:00

  • Characterization of covalent binding of tyrosine kinase inhibitors to plasma proteins.

    abstract：:Eight covalent tyrosine kinase inhibitors (TKIs) were investigated to determine the characteristics of their covalent binding to plasma proteins. The data revealed that their covalent binding to plasma proteins is of species difference. In addition to the reports on neratinib and pyrotinib, osimertinib, alflutinib, AS...

    journal_title：Drug metabolism and pharmacokinetics

    pub_type： 杂志文章

    doi：10.1016/j.dmpk.2020.07.002

    authors： Liu X,Feng D,Zheng M,Cui Y,Zhong D

    更新日期：2020-10-01 00:00:00